Shop Now Contact

Anti-Human Claudin 18.2 (Zolbetuximab Biosimilar)

Cat # Size Price Quantity
5067011 mg$190
5067025 mg$590
50670320 mg$1800

  Bulk/Custom

Product Details

CloneZolbetuximab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human Claudin 18.2 (Zolbetuximab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman Claudin 18.2
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
RRIDAB_3739342
Target NameCLDN18.2, Claudin 18, Claudin-18 splice variant 2
Antibody TypeRecombinant
Research AreasCancer Marker, Epithelial cells
See All FormatsClone Zolbetuximab

Background Information

Zolbetuximab is a chimeric monoclonal antibody of the immunoglobulin G1 kappa (IgG1κ) subclass that specifically targets claudin‑18 isoform 2 (CLDN18.2), a tight‑junction protein belonging to the claudin family. Structurally, it is a recombinant glycoprotein with an approximate molecular weight of 148 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, producing the canonical Y‑shaped configuration typical of IgG antibodies. It is generated using mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper folding, glycosylation, and assembly consistent with humanized antibody architecture.

The variable domains of the heavy (VH) and light (VL) chains contain complementarity‑determining regions (CDRs) that define the antibody’s high‑affinity binding to an extracellular epitope on CLDN18.2. These CDRs form the paratope that engages the target via hydrogen bonding, electrostatic complementarity, and hydrophobic interactions. CLDN18.2 is a membrane‑spanning component of tight junctions, composed of four transmembrane helices and two extracellular loops. Upon binding, Zolbetuximab recognizes conformational epitopes within one of these extracellular loops, allowing selective interaction with the surface‑exposed form of the protein while avoiding other claudin isoforms. In cellular studies, this precise recognition can trigger conformational effects on the tight‑junction architecture and facilitate immune effector engagement.

The Fc (fragment crystallizable) region of Zolbetuximab, derived from the human IgG1 isotype, mediates interactions with Fc gamma receptors (FcγRs) on immune effector cells and complement component C1q, contributing to effector mechanisms such as antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC) in in‑vitro models. Additionally, the Fc domain confers molecular stability and extends serum half‑life through binding to neonatal Fc receptors (FcRn), which recycle IgG molecules. Overall, Zolbetuximab exemplifies rational chimeric antibody design combining specific epitope targeting, IgG1 structural integrity, and immune effector potential, serving as a model for studying tight‑junction protein interactions and receptor‑mediated cytotoxic mechanisms.

Data Sheets

Anti-Human Claudin 18.2 (Zolbetuximab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.